The Alzheimer’s Disease Clinical Spectrum: Diagnosis and Management

https://doi.org/10.1016/j.mcna.2018.10.009 Get rights and content
Under a Creative Commons license
open access

Keywords

Alzheimer’s disease
Mild cognitive impairment
Cognitive
Treatment
Donepezil
Memantine
Neuroimaging
Review

Cited by (0)

Disclosure Statement: Dr. Atri has no equity, shares or salary from any pharma company and is not a member of any pharma speakers’ bureau. He has received honoraria for consulting, educational lectures/programs/materials or advisory boards from AbbVie, Allergan, Alzheimer’s Association, Biogen, Eisai, Grifols, Harvard Medical School Graduate Continuing Education, Lundbeck, Merck, Oxford University Press (medical book-related revenues), Sunovion, Suven, and Synexus. Dr. Atri’s institution (Banner Health) has investigational observational study/trial related funding from Novartis. Dr. Atri’s previous institution (California Pacific Medical Center) had contracts or received investigational clinical trial related funding from The American College of Radiology, AbbVie, Avid, Biogen, Lilly, Lundbeck, Merck, and vTV.